Analyst Richard Close of Canaccord Genuity maintained a Buy rating on Privia Health Group, retaining the price target of $32.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Richard Close has given his Buy rating due to a combination of factors that highlight Privia Health Group’s strong performance and potential for future growth. The company demonstrated impressive results in the Medicare Shared Savings Program (MSSP), achieving a significant 32% increase in savings compared to the previous year. This success led Privia to raise its 2025 adjusted EBITDA guidance, indicating confidence in continued financial improvement.
Additionally, Privia’s track record in value-based care programs is noteworthy, with its Mid-Atlantic ACO achieving the highest savings rate among large ACOs. The company’s ability to maintain expenditures well below median ACO performance and Medicare FFS benchmarks further underscores its operational efficiency. These factors, combined with Privia’s potential for geographic expansion and its position as a 2025 Focus Stock, support the Buy rating from Richard Close.
Close covers the Healthcare sector, focusing on stocks such as Quipt Home Medical, Hinge Health, Inc. Class A, and Omada Health, Inc.. According to TipRanks, Close has an average return of 10.6% and a 50.10% success rate on recommended stocks.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $30.00 price target.